Cosciens raises approximately USD 12 million in unsecured convertible debenture offering

• Cosciens Biopharma has issued approximately USD 12 million of 15% unsecured convertible debentures under its ongoing private placement.
• The offering targets up to USD 20 million; marketing is expected to continue through mid-November unless fully subscribed sooner.
• Proceeds raised and existing cash cover the remaining USD 6 million Nualtis acquisition payment due to AtaiBeckley in March 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosciens Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610190800PRIMZONECNPR____9848214) on October 19, 2026, and is solely responsible for the information contained therein.